Research and development of bronchodilators for asthma and COPD with a focus on G protein/KCa channel linkage and β2-adrenergic intrinsic efficacy

Pharmacol Ther. 2015 Dec:156:75-89. doi: 10.1016/j.pharmthera.2015.09.004. Epub 2015 Sep 30.

Abstract

Bronchodilators are used to improve symptoms and lung function in asthma and COPD. Airway smooth muscle tone is regulated by both muscarinic and β2-adrenergic receptor activity. Large-conductance Ca(2+)-activated K(+) (KCa) channels are activated by β2-adrenergic receptor agonists, via Gs, and suppressed by muscarinic receptor antagonists via Gi. This functional antagonism converges on the G protein/KCa channel linkages. Membrane potential regulated by KCa channels contributes to airway smooth muscle tension via Ca(2+) influx passing through voltage-dependent Ca(2+) (VDC) channels. The Gs/KCa/VDC channel linkage is a key process in not only physiological effects, but also in dysfunction of β2-adrenergic receptors and airway remodeling. Moreover, this pathway is involved in the synergistic effects between β2-adrenergic receptor agonists and muscarinic receptor antagonists. Intrinsic efficacy is also an important characteristic for both maintenance and loss of β2-adrenergic action. Allosteric modulators of G protein-coupled receptors contribute not only to this synergistic effect between β2-adrenergic and muscarinic M2 receptors, but also to intrinsic efficacy. The effects of weak partial agonists are suppressed by lowering receptor number, disordering receptor function, and enhancing functional antagonism; in contrast, those of full or strong partial agonists are not suppressed. Excessive exposure to full agonists causes β2-adrenergic desensitization; in contrast, exposure to partial agonists does not cause desensitization. Intrinsic efficacy may provide the rationale for the clinical use of β2-adrenergic receptor agonists in asthma and COPD. In conclusion, the G protein/KCa linkage and intrinsic efficacy (allosteric effects) may be therapeutic targets for research and development of novel agents against both airway obstruction and airway remodeling.

Keywords: Airway smooth muscle; Allosteric modulators of G protein-coupled receptors; Ca(2+)-activated K(+) channels; Muscarinic receptor antagonists; Voltage-dependent Ca(2+) channels; β(2)-adrenergic receptor agonists.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / pharmacology*
  • Asthma / drug therapy*
  • Bronchodilator Agents / pharmacology*
  • Calcium Channels / metabolism
  • Dose-Response Relationship, Drug
  • GTP-Binding Proteins / metabolism
  • Humans
  • Inflammation / drug therapy
  • Inflammation / physiopathology
  • Muscarinic Antagonists / pharmacology*
  • Muscle, Smooth / metabolism
  • Phosphorylation / physiology
  • Potassium Channels, Calcium-Activated / metabolism
  • Pulmonary Disease, Chronic Obstructive / drug therapy*

Substances

  • Adrenergic beta-Antagonists
  • Bronchodilator Agents
  • Calcium Channels
  • Muscarinic Antagonists
  • Potassium Channels, Calcium-Activated
  • GTP-Binding Proteins